Regeneron halts enrollment in prostate cancer trial following two deaths
jamesbenet

Regeneron Pharmaceuticals (NASDAQ:REGN) has stopped enrollment in a trial exploring a combination of the company's Libtayo (cemiplimab) and the candidate REGN5678 following two patient deaths.
The pharma said one of the deaths just occurred in July. The deaths occurred in a cohort receiving REGN5678 plus high-dose Libtayo. REGN 5678 is a bispecific antibody targeting PSMA and CD28

"The Company plans to explore REGN5678 combinations with lower doses of Libtayo," Regeneron (REGN) said in a 10Q filing. "The Company also plans to enroll patients in a REGN5678 monotherapy cohort, as well as in combination with other immunotherapy modalities."

More on Regeneron

Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront
Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check